What is it about?

Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy September 2015 - Journal of the Neurological Sciences 357(1):e181 DOI: 10.1016/j.jns.2015.08.623 Presented: At the XXII WCN World Cancer Congress. Santiago, Chile.

Featured Image

Why is it important?

Quality of life + Impact of cancer + cancer therapy on the central and peripheral nervous system; Neurology needs to adapt the current practice to the reality of novel therapy.

Perspectives

Novel Therapies as Immunotherapy and Targeted TherapyTreatment/Management of Primary Brain Tumors.

Dr Catherine Maurice
University of Toronto

Read the Original

This page is a summary of: Nras-mutated primary leptomeningeal melanomatosis in the era of targeted chemotherapy, Journal of the Neurological Sciences, October 2015, Elsevier,
DOI: 10.1016/j.jns.2015.08.623.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page